# Comparison of AVD + Low-Dose Nivolumab vs. PET-Adapted BEACOPP-like in Advanced cHL

> **NCT07234487** · PHASE2 · RECRUITING · sponsor: **St. Petersburg State Pavlov Medical University** · enrollment: 178 (estimated)

## Conditions studied

- Hodgkin Lymphoma

## Interventions

- **DRUG:** Nivo-AVD
- **DRUG:** BEACOPP-like

## Key facts

- **NCT ID:** NCT07234487
- **Lead sponsor:** St. Petersburg State Pavlov Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-14
- **Primary completion:** 2029-10
- **Final completion:** 2030-10
- **Target enrollment:** 178 (ESTIMATED)
- **Last updated:** 2026-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07234487

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07234487, "Comparison of AVD + Low-Dose Nivolumab vs. PET-Adapted BEACOPP-like in Advanced cHL". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07234487. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*